Nasdaq
$24.19▲ 0.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.75BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 2d agoPre-market26.10.23 19:068-KKey event#●●●#●●●#●●●
Zai Lab Ltd
Zai Lab entered into a securities purchase agreement on October 22, 2026, to raise approximately $250 million through a private placement of 11.34 million American Depositary Shares (ADSs) at a price of $22.04 per ADS. The company intends to use the net proceeds primarily to fund the global development of its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (zoci).…more
$24.19+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:444Ownership
Zai Lab Ltd
Zai Lab Ltd insider Chen Yajing filed a Form 4 on October 5, 2026, reporting a change in beneficial ownership of securities effective October 1, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$24.19+0.54%vs prev closeView filingShare - 8.21After-hours26.08.22 05:164Ownership
Zai Lab Ltd
Zai Lab Ltd insider Chen Yajing filed a Form 4 report on August 21, 2026, regarding a change in beneficial ownership of company securities that occurred on August 19, 2026. This filing serves as an official disclosure of the insider's updated stock holdings.…more
$24.19+0.54%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 19:36#●●●#●●●#●●●
Zai Lab Reports 81.8% Response Rate in Phase 1b SCLC Trial
Zai Lab announced positive Phase 1b data for its SCLC treatment, achieving an 81.8% objective response rate. The company plans to advance the therapy to a global Phase 3 study by the end of 2026.…more
$24.19+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoOvernight26.10.23 15:30
●●●●●●●● ●●●●● ●●●●●●
Zai Lab has announced a $250 million PIPE financing deal to fund the development of its Zoci drug candidate. The issuance of 11.34 million ADSs will result in equity dilution for existing shareholders.…more
$24.19+0.54%vs prev closeShareBenzinga - 10.14Pre-market26.10.14 20:12
●●●●●●●● ●●●●● ●●●●●●
Zai Lab is scheduled to present initial Phase 1/1b clinical data for its atopic dermatitis candidate, ZL-1503, on November 13. The presentation will focus on results from healthy volunteers as the company advances its drug development pipeline.…more
$24.19+0.54%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report